Dr. Marty Makary Resigns as FDA Commissioner
Dr. Marty Makary has resigned from his position as the commissioner of the U.S. Food and Drug Administration (FDA), as confirmed by President Donald Trump on May 12. In a social media post, Trump revealed that Makary had informed him of his decision to step down, effective Tuesday. While Makary did not offer an explicit reason for his resignation, Trump praised his leadership, calling him a “hard worker” who was “respected by all.”
In a subsequent post, Trump assured the public that Makary would continue to have a successful career in medicine, adding that much had been accomplished under his leadership. He also confirmed that Kyle Diamantas, the FDA’s deputy commissioner for food, would serve as the acting FDA commissioner.
Trump Defends Makary’s Leadership Amid Criticism
President Trump faced questions regarding the resignation but refused to clarify whether Makary resigned voluntarily or was dismissed. The resignation comes after a series of controversies surrounding the FDA’s decisions on drug approvals, particularly in relation to a cancer drug developed by Replimune and the review of the abortion drug mifepristone. Trump reiterated his confidence in Makary’s decisions, which he defended in television interviews, asserting that they were based on evidence and not influenced by external pressures.
The resignation of Makary follows the earlier departure of Dr. Vinay Prasad, the FDA’s top vaccine official. Prasad and Makary were close friends, and their exits have raised questions about the leadership stability at the FDA.
Political Pressure and the Impact on Health Nominees
The resignation also comes amidst ongoing difficulties faced by Trump in confirming his health-related nominees. Trump had previously nominated Dr. Casey Means for surgeon general, but he withdrew her nomination, opting instead to select Dr. Nicole Saphier. Additionally, Sen. Bill Cassidy (R-La.), who chairs the Senate Health Committee, has been involved in contentious debates over vaccine policies with Health Secretary Robert F. Kennedy Jr., particularly as he faces a contested primary in Louisiana.
Meanwhile, the Senate committee has yet to move on Dr. Erica Schwartz’s nomination for director of the Centers for Disease Control and Prevention (CDC), following the departure of Trump’s first CDC director, Susan Monarez, just a month into her tenure. Trump’s handling of health nominations and appointments remains a focal point as the administration continues to navigate public health and policy challenges, particularly in the wake of the ongoing Iran war and the global COVID-19 pandemic.
With leadership changes and the continued scrutiny of the FDA, questions about the future direction of U.S. health policy and the role of the FDA in drug approvals remain central to the national conversation.
